Läkemedelsverket ordnar tillsammans med Karolinska Institutet en genuskonferens den 15 oktober i Stockholm med rubriken "Sex, Gender and Drugs".
Pris: Ingen avgift. Kaffe ingår, men ej lunch.
Anmälan: via Karolinska Institutet. Sista anmälningsdag 10 oktober.
Plats: Nobel Forum, Karolinska Institutet, Stockholm
Program
Is there a gender bias in how we treat men and women with cardiovascular disease, rheumatism or depression and do guidelines need to consider differences between the sexes? Are there any differences in pharmacokinetics between the sexes and how do competent authorities consider gender specific issues during drug evaluation?
These are some of the issues that will be highlighted on the conference arranged by Center for Gender Medicine, Karolinska Institutet and the Swedish Medical Products Agency.
8:30-9:00 Coffee and registration
9:00 Welcome
Karin Schenck-Gustafsson, Center for Gender Medicine, Karolinska Institutet
Catarina Andersson Forsman, HSF, Stockholm County Council
Johan Bratt, Karolinska University Hospital
9:20 Pharmacokinetics in real life
Chair: Erik Eliasson
9:20-9:55 Sex and gender differences in pharmacokinetics
Donald Mattison, National Institute of Health, Bethesda, Washington DC
9:55-10:20 Sex, gender and alcohol
Anders Helander, Karolinska Institutet
10:20-10:45 Estimating renal function in men and women
Gunnar Sterner, Lund University, SBU
10:45-11:00 Coffee and fruit
11:00 Sex and gender aspects in treating disease
Chair: Mia von Euler
11:00-11:25 Gender differences in depressive disorders
Sten Thelander, Stockholm Psychiatry South
11:25-11:50 Gender differences in medical management of three inflammatory diseases: Rheumatoid arthritis, Chron’s disease and Psoriasis
Ronald van Vollenhoven, Karolinska University Hospital
11:50-12:15 Cardiovascular disease
Karin Schenck-Gustafsson, Karolinska Institutet
12:15–13:15 Lunch break
13:15 Drug utilization
Chair: Ulf Bergman
13:15-13:40 Gender and adverse drug reactions
Diana Rydberg, Karolinska Institutet
13:40-14:05 Gender differences in bleeding during antiplatelet and anticoagulant treatment
Paul Hjemdahl, Karolinska Institutet
14:05-14:30 The SALAR-project “Gender button” (HÅJ)
Björn Wettermark, Desirée Loikas, Karolinska Institutet
14:30-14:50 Coffee
14:50 Regulatory aspects
Chair: Charlotte Asker-Hagelberg
14:50-15:25 FDA: Gender and drug development
Marsha Henderson, Food and Drug Administration, Silver Spring, Washington DC
15:25-15:50 Europe: Regulatory strategy on gender
Jane Ahlqvist-Rastad, Swedish Medical Products Agency
15:50-16:15 Regulatory aspects on gender and pharmacokinetics
Monica Edholm, Swedish Medical Products Agency
16:15-16:40 Ethical aspects of clinical trials in adolescent girls in Europe
Viveca Odlind, Swedish Medical Products Agency
16:40 Concluding remarks
Christina Åkerman, Swedish Medical Products Agency